This course has expired. View available courses.
Neurology, Pain
CGRP Inhibition: A new era in migraine prevention
This 30-minute RACP accredited activity aims to equip physicians in determining which patients may benefit from preventative migraine therapies such as CGRP inhibitors. Featuring a case study and video interview from Neurologist, Associate Professor Richard Stark.
DURATION
0.5 hrs
PROFESSION
Specialist
# OF CREDITS
0.5
ACCREDITATION
RACP
EXPIRY DATE
2022-06-27
This 30-minute RACP accredited activity aims to equip physicians in determining which patients may benefit from preventative migraine therapies such as CGRP inhibitors. Featuring a case study and video interview from Neurologist, Associate Professor Richard Stark.
Faculty
A/Prof Richard Stark,
AM, MB, BS, FRACP Neurologist
Learning objectives
Upon completion of this program, participants will be able to:
- Understand the positive impact they can have on the quality of life (QOL) of migraine patients through timely intervention/escalation of therapy.
- Understand how the introduction of calcitonin gene related peptide (CGRP) inhibitors has changed the treatment paradigm in migraine prevention.
- Identify patients who could benefit from timely introduction of a CGRP inhibitor.
- Reduce the risk of oral medication overuse in their patients and minimise the unnecessary complexity of managing patients with oral medications.
- Discuss the rapid impact that CGRP inhibitors can have on the QOL of people with migraine.